ARTICLE | Politics & Policy
Payers vs. drug makers on HCV drug costs
July 30, 2014 1:12 AM UTC
Dueling reports released by groups representing drug makers on one side and payers on the other, highlight the benefit of new HCV treatments as well as the cost. Sovaldi sofosbuvir from Gilead Science...